Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

816 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Use of intravenous iron and risk of anaphylaxis: A multinational observational post-authorisation safety study in Europe.
Fortuny J, von Gersdorff G, Lassalle R, Linder M, Overbeek J, Reinold J, Toft G, Timmer A, Dress J, Blin P, Droz-Perroteau C, Ehrenstein V, Franzoni C, Herings R, Kollhorst B, Moore N, Odsbu I, Perez-Gutthann S, Schink T, Rascher K, Rasouliyan L, Rothman KJ, Saigi-Morgui N, Schaller M, Smits E, Forstner M; Intravenous Iron Consortium; Bénichou J, Bircher AJ, Garbe E, Rampton DS, Gutierrez L. Fortuny J, et al. Among authors: linder m. Pharmacoepidemiol Drug Saf. 2021 Oct;30(10):1447-1457. doi: 10.1002/pds.5319. Epub 2021 Jul 12. Pharmacoepidemiol Drug Saf. 2021. PMID: 34181291 Free PMC article.
Characterization of new users of cilostazol in the UK, Spain, Sweden, and Germany.
Castellsague J, Perez-Gutthann S, Calingaert B, Bui C, Varas-Lorenzo C, Arana A, Prados-Torres A, Poblador-Plou B, Gonzalez-Rubio F, Giner-Soriano M, Roso-Llorach A, Linder M, Citarella A, Scholle O, Blenk T, Garbe E. Castellsague J, et al. Among authors: linder m. Pharmacoepidemiol Drug Saf. 2017 Jun;26(6):615-624. doi: 10.1002/pds.4167. Epub 2017 Jan 30. Pharmacoepidemiol Drug Saf. 2017. PMID: 28133890 Free PMC article.
Effectiveness of risk minimization measures for the use of cilostazol in United Kingdom, Spain, Sweden, and Germany.
Castellsague J, Poblador-Plou B, Giner-Soriano M, Linder M, Scholle O, Calingaert B, Bui C, Arana A, Laguna C, Gonzalez-Rubio F, Roso-Llorach A, Prados-Torres A, Perez-Gutthann S. Castellsague J, et al. Among authors: linder m. Pharmacoepidemiol Drug Saf. 2018 Sep;27(9):953-961. doi: 10.1002/pds.4584. Epub 2018 Jul 25. Pharmacoepidemiol Drug Saf. 2018. PMID: 30043552 Free PMC article.
Patterns of use of antimuscarinic drugs to treat overactive bladder in Denmark, Sweden, and the United Kingdom.
Margulis AV, Linder M, Arana A, Pottegård A, Berglind IA, Bui CL, Kristiansen NS, Bahmanyar S, McQuay LJ, Atsma WJ, Appenteng K, D'Silva M, Perez-Gutthann S, Hallas J. Margulis AV, et al. Among authors: linder m. PLoS One. 2018 Sep 27;13(9):e0204456. doi: 10.1371/journal.pone.0204456. eCollection 2018. PLoS One. 2018. PMID: 30260993 Free PMC article.
A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder.
Phiri K, Hallas J, Linder M, Margulis A, Suehs B, Arana A, Bahmanyar S, Hoffman V, Enger C, Horter L, Odsbu I, Olesen M, Perez-Gutthann S, Kristiansen NS, Appenteng K, de Vogel S, Seeger J. Phiri K, et al. Among authors: linder m. Curr Med Res Opin. 2021 May;37(5):867-877. doi: 10.1080/03007995.2021.1891035. Epub 2021 Mar 8. Curr Med Res Opin. 2021. PMID: 33591859
Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study.
Hoffman V, Hallas J, Linder M, Margulis AV, Suehs BT, Arana A, Phiri K, Enger C, Horter L, Odsbu I, Olesen M, Perez-Gutthann S, Xu Y, Kristiansen NS, Appenteng K, de Vogel S, Seeger JD; mirabegron PMR-PASS study group. Hoffman V, et al. Among authors: linder m. Drug Saf. 2021 Aug;44(8):899-915. doi: 10.1007/s40264-021-01095-7. Epub 2021 Jul 8. Drug Saf. 2021. PMID: 34236595 Free PMC article.
816 results